Does Sweating Make Eczema Worse? Japan's 2024 Guideline Says the Advice Has No Evidence

Why keep treating skin that looks clear?

There are two approaches. Reactive therapy means applying treatment only to skin with visible lesions and stopping or tapering quickly once they clear or nearly clear. Proactive therapy starts after an acute flare has been treated and the lesions have successfully resolved. The European guideline, EuroGuiDerm's 2025 document, defines it as a combination of predefined, long-term anti-inflammatory treatment applied usually twice a week to previously affected areas of skin, together with liberal daily use of emollients on the entire body, with the duration matched to severity and persistence.

The last clause of that definition is what settles the character of the whole thing. It is marked by a predefined appointment schedule for clinical examinations. This is not a routine you keep going by yourself indefinitely; it is a management plan with review visits built into its definition. Japan's guideline states the same condition in different words, saying it is desirable for proactive therapy to be carried out by a physician well versed in assessing the skin signs of atopic dermatitis, or in coordination with one, because the area to be treated, the timing of the shift from daily to intermittent application, and when to stop all require case-by-case decisions.

So why treat skin that looks fine. Japan's guideline answers with pathology. In atopic dermatitis, skin where inflammation has settled and which appears normal to the eye often still has inflammatory cells remaining histologically, leaving it in a state where external or internal factors easily provoke inflammation again. That one sentence carries the logic of maintenance therapy. Skin that looks healed is not necessarily healed. The same guideline also says when to make the switch to intermittent application: the dermatitis must be sufficiently improved, with no itch and no erythema, and no fine elevation of the skin detectable even by touch.

On safety, the sentence Japanese dermatologists wrote is one you cannot quote only the first half of. Thirteen randomized controlled trials and one systematic review indicated the approach is useful for maintaining remission, so the evidence level was graded A, and many reports found no significant difference in adverse events compared with vehicle application over observation periods of up to 20 weeks for corticosteroids and up to one year for tacrolimus, making it a treatment considered to be comparatively safe. But no examination has been carried out beyond those periods, and careful observation for the appearance of side effects is necessary. Drop the observation windows and you have the guideline saying something it did not say.

How do the guidelines differ?

Table: atopic dermatitis and eczema management guidelines compared by country, covering proactive therapy, emollient quantity, bathing temperature, bleach baths and wet wrapping.

Three things go with this table. First, the five documents were not published at the same time. Four are from 2023 to 2025, and the publication and last-update years of the UK's NICE CG57 are something this article could not verify. Part of the difference may be revision timing rather than philosophy. The UK document also covers children under 12; a UK guideline for adults was not obtained. Second, the two bath temperature figures have not been traced back to their source literature. The Korean guideline moved that detail to supplementary material, which was not obtained, and in the European guideline 27 to 30C appears as the temperature for a rapid rinse performed in the bath. This is not a table for deciding who is right. Third, none of these guidelines was written for a reader in another country. Rather than picking the box you like best and rewriting your own routine, the more useful move is showing that wording to the clinician who treats you.

United States: the bill rather than the guideline

US

The American numbers in this article come from an invoice, not a recommendation. Between November 14 and December 21, 2019, an online survey collected responses from 1,118 US adults aged 18 and over who either had atopic dermatitis themselves or were the primary caregiver of someone who did, recruited through a patient organization. Adult patients made up 77.5%, caregivers of children and young adults 22.5%.

Median annual out-of-pocket spending was $600, with a range from $0 to $200,000. Above $1,000 a year: 41.9%. Above $5,000: 8.5%. The categories where money went out of pocket are the part worth reading slowly. Moisturizers and emollients came first at 94.3%, followed by hygiene and bathing products at 85.0%, allergy medications at 75.1%, specialty cleaning products at 74.7%, visit deductibles at 68.7% and prescription copays at 64.3%. And 48.6% had paid out of pocket for prescription medication their insurance did not cover.

This is not a figure representing the US population. It is an online survey of patient-organization members, six years old, with a spread wide enough that the median carries most of the meaning. One line survives that caveat anyway. In the same period that UK guidance was setting a weekly prescribing quantity for emollients in active eczema, moisturizers were the single item American respondents were most likely to be buying themselves. What US clinical guidance actually recommends, on proactive therapy and bleach baths, sits in the tables and sections around this one, because for a reader in the United States that part is already familiar and the invoice is not.

Japan: school showers, sweat, and an admission to learn how to apply cream

JP

A few items in the Japanese guideline have no counterpart in the other three. The first is that showering itself is the subject of a recommendation. Showering is useful for improving the symptoms of atopic dermatitis, at recommendation grade 1 and evidence level B, and the supporting evidence includes three domestic Japanese intervention studies of tap-water showers taken at school by children with atopic dermatitis. All three significantly improved symptoms, and the effect is considered easier to obtain in seasons with more sweating. One report confirmed a significant reduction in Staphylococcus aureus colony counts on the skin four weeks after the intervention began. No adverse events were reported. An intervention that changes the environment rather than the prescription, sitting in a medical society's evidence list.

The meta-analysis cited in the same section contradicts a widely held belief head-on. Disease severity in patients receiving bathing or showering therapy decreased from baseline at at least one time point, and in qualitative analysis, bathing or showering seven or more times a week produced significant improvement in investigator-assessed severity, lesion extent and itch. Yet no statistically significant difference in effectiveness was found between seven or more times a week and fewer, and no association was found between daily showering or bathing and worsening severity. Determining an optimal frequency, the guideline says, would need larger trials.

The passage on sweating is blunter. There is no evidence that instructing patients to avoid sweating improved symptoms, and such instruction is unnecessary. What matters instead is guidance on dealing with sweat after the fact, and in cases where sweating is reduced, becoming able to sweat can be one of the goals treatment reaches for. Avoiding sweat is not the plan; building an environment where you can wash after sweating is, which is the same logic as the school shower section.

Water temperature comes with a stated reason. For bathing and showering, 38 to 40C is described as good, being the optimal temperature reported for recovery of skin barrier function, and water at 42C or above cannot be recommended because it causes leaching of sebum and natural moisturizing factors and provokes itch. That sits 10 degrees away from the Korean guideline's figure, and for the reason given earlier it cannot be read as one of them being correct. On emollients, twice daily in the morning and evening gives better moisturizing effect than once, one of the two applications is desirably straight after bathing, and application to the whole body including areas that look normal is described as desirable, because the skin of a patient with atopic dermatitis is dry with high transepidermal water loss even where it appears unaffected.

The box moisturizer sits in is different here as well. The guideline carries a table of the main topical skin-care preparations used for moisturizing and protection, listing generic names: heparinoid-containing preparations and urea preparations for moisturizing the skin surface, white petrolatum and zinc oxide ointment for protecting it. That prescription emollients exist as medicinal products and appear in a society guideline table by generic name is as far as this article's verification goes. Patient cost share was not confirmed.

Soap gets a conditional recommendation rather than a rule. At recommendation grade 1 and evidence level C, the use of soap and cleansers is considered useful for managing atopic dermatitis if skin condition, the type of product and the washing method are taken into account. In practice: where dryness is severe, whether by case, body site or season, or where a soap is strongly irritating, keep soap use to a minimum and rinse thoroughly with water that is not too hot. Conversely, for oily skin, sebum-rich sites, or sites with repeated skin infection, consider active use of a cleanser. There is no evidence that bar soap or synthetic-surfactant liquid cleanser is superior to the other. Lather well, wash in a way that minimizes mechanical irritation, and rinse so that no cleanser remains. The evidence attached is a trial in well-controlled children with atopic dermatitis in whom one limb pair was washed with soap and the other with water only for four weeks in autumn and winter, with no difference in eruption scores between the two sides.

Two smaller items are worth having. Residue from ointments based on fats such as petrolatum can be difficult to remove with soap or cleanser, and the guideline says applying something like olive oil to the areas where residue is bothersome can be considered as a way to deal with it. None of the other three national guidelines contained this. And mixing two or more topical preparations on your own, such as combining a topical corticosteroid with an emollient, should not be done casually, because changes in drug stability and percutaneous absorption are anticipated.

Coordination with schools is handled through a form. Kindergartens, nurseries and schools are approached using an allergic disease living-management instruction sheet, which has fields for the patient's usual treatments, severity, and the accommodations needed at school, and which is completed by the treating physician. Examples of accommodations the guideline gives include wiping down with a damp towel after sweating, showering if possible, and applying emollient in winter when dryness is severe.

Then there is admission. The Japanese guideline has a section titled indications for inpatient treatment. In cases where severe dermatitis drags on chronically, the background usually involves the activity of the disease itself, the problem of aggravating factors, and problems of patient adherence, interacting until the situation is deadlocked. The adherence problems it lists include insufficient understanding of the condition and of treatment methods, never having experienced what remission feels like and so no longer knowing what the treatment goal is, an empirically formed misconception that applying treatment does not help, insufficient understanding of the purpose and technique of topical therapy, and avoidance of corticosteroids. Admission allows separation from the everyday environment so topical therapy can be carried out thoroughly, a relationship of trust between patient and clinician to be established with time to spare, and aggravating factors, application technique and skin-care methods to be reviewed. Multiple institutions have confirmed that this kind of intervention improves long-term prognosis after discharge, and the guideline says it can be considered for moderate cases as needed. Its list of patient-guidance methods includes a short educational admission.

Corticosteroid anxiety has its own subsection too. Fear and avoidance arising from misunderstanding frequently reduce adherence, and the guideline names two specific sources: confusion with the side effects of oral corticosteroids, and confusion between worsening of the atopic dermatitis itself and side effects of the topical corticosteroid. It adds that incorrect technique can also leave patients feeling no effect and developing distrust. And the guideline defines what treatment is aiming at: reaching and maintaining a state with no symptoms, or symptoms so slight that daily life is unimpeded and drug therapy is not much needed, and where that level is not reached, maintaining a state where symptoms stay slight or mild and no sudden worsening disrupts daily life.

South Korea: EASI 23 as a line

KR

The Korean guideline from 2025 is the only one of the five that opens the proactive frequency to three. It recommends a moderate-potency topical corticosteroid or a topical calcineurin inhibitor two to three times a week on improved areas to prevent flares or relapses, at recommendation strength A, evidence 1a, with 94% expert agreement. Bathing is daily, in warm or lukewarm water at 27 to 30C, for 5 to 10 minutes, avoiding vigorous scrubbing, with non-soap cleansers of neutral to acidic pH preferred over alkaline soaps to preserve the skin barrier. For acutely flared lesions it suggests considering wet wrap therapy using diluted topical corticosteroid, at recommendation strength B.

The same guideline names the obstacles to treatment out loud. Misconceptions such as steroid phobia, unwarranted dietary restrictions and reliance on unproven treatments hinder adherence, worsening disease control and increasing treatment costs. Which is why it puts a structured education programme delivered by a multidisciplinary team at recommendation strength A.

What distinguishes Korea institutionally is that the line is drawn as an integer. The reimbursement criteria for biologics require, for adolescents and adults 12 and over, severe atopic dermatitis persisting three years or more, failure to respond to a moderate to high potency topical corticosteroid or topical calcineurin inhibitor over at least four weeks, an inadequate response to a systemic immunosuppressant over at least three months, and an EASI score of 23 or above. For children aged 6 to 11 the thresholds are one year of severe disease, four weeks of failed topical treatment and EASI 21 or above; for ages six months to five years the same without the duration requirement. The guideline's own sentence is dry about what follows. Patients meeting these criteria receive partial reimbursement with a 10% co-payment, while those who do not qualify must cover the full treatment cost. Corresponding reimbursement thresholds in the other countries were not obtained, so the accurate reading is that Korea has such a line, not that only Korea does.

The diagnostic code for severe atopic dermatitis, L20.85, was created in July 2020 and took effect in January 2021, bringing the condition under a special cost-sharing scheme that sets the patient's share of treatment costs at 10% for both inpatient and outpatient care.

Moisturizer sits somewhere else again. A public health centre document from the city of Paju, covering allergy medical expense support, classifies moisturizers as a non-covered item excluded from general support while simultaneously stating that for atopic dermatitis, up to three moisturizers a year are supported. Eligibility runs to residents 18 and under with allergic disease at or below 80% of median income, the qualifying codes are L20 for atopic dermatitis and J45 and J46 for asthma, and the annual ceiling is 200,000 won per person. Students at designated allergy-safe schools can be supported on a recommendation letter regardless of income, one per institution. The structure is a gap filled by a separate budget line because the item is not covered. What was verified is one municipal document. The national coverage status was not.

United Kingdom: 250 grams a week, and a regulator that looked at withdrawal

GB

The most quotable line in UK guidance is a quantity. Prescribe large quantities of leave-on emollients, 250g to 500g weekly, and make them easily available for use in nurseries, playgroups and schools. Children with atopic eczema and their carers should be told that they need to use much larger amounts of emollient than other treatments, more often, and that emollients should be used on the whole body even when the eczema is clear and while all other treatments are being used. The provision of emollients is separately designated as a quality standard statement.

The framework around it is stepped care. Emollients are the basis of management and should always be used, even when atopic eczema is clear, with treatment stepped up and down according to severity. Topical corticosteroids are to be prescribed for application only once or twice daily, with potency matched to severity: mild for mild disease, moderate for moderate, potent for severe. On wet wraps and occlusive dressings this is the most conservative of the four: do not use them as first-line treatment, use them with topical corticosteroids for 7 to 14 days if used at all, and seek specialist dermatological advice before continuing. Proactive therapy carries the same tone. Not a recommendation but a suggestion to consider, for children with frequent flares of two or three a month, at two consecutive days per week rather than twice weekly, with a review in three to six months.

Two caveats belong here rather than in a footnote. This document covers children under 12, and its publication and last-update years were not verified for this article. There is an obvious temptation to explain British caution through national character or health-service philosophy. The fact that the other four documents date from 2023 to 2025 explains just as much, and filling an unverified gap with personality is the worse option.

Being a country that prescribes emollients also has a boundary. NHS England's policy guidance on items that should not routinely be prescribed in primary care states that patients with mild dry skin can be successfully managed using over-the-counter products on a long-term basis, then sets out the exceptions where prescribing remains appropriate. Those include eczema, dermatitis or psoriasis which is in an active stage in need of treatment, ichthyosis, and cases where emollients are needed to complement other treatments such as phototherapy. The general exception framework covers long-term condition management, minor conditions in a complex form, complex situations including immunosuppression, and patients whose ability to self-manage is impaired by medical, mental health or significant social vulnerability. A UK patient organization notes that some local commissioners and general practitioners misread the guidance as instructing them not to prescribe emollients to eczema patients at all.

Few documents show the location of that boundary this plainly. Mild dry skin you buy yourself; active eczema in need of treatment is prescribed. No country argues about whether atopic dermatitis is a disease. The line gets drawn across the item that is its first-line treatment.

Elsewhere the argument is about the condition itself. British dermatology guidance classes male pattern hair loss as cosmetic, so the NHS does not usually treat it, while the same country's regulator did the most detailed work on that drug's risks: what works for hair loss, and why the warnings differ by country. And in acne the line moved onto the price tag, with two drugs kept at a weaker recommendation because of cost rather than weaker evidence.

The second reason the UK belongs in this article is regulatory. On September 15, 2021 the UK medicines regulator published a drug safety update on topical steroid withdrawal reactions. Reviewing adverse-reaction reports from 1963 to 2020 alongside evidence from patients, healthcare professionals and the literature, it concluded that prolonged, continuous or inappropriate use of topical corticosteroids, particularly moderate to high potency products, can cause rebound flares. The described features are specific: burning rather than itch as the main symptom, redness that is confluent rather than patchy, spread beyond the area first treated, occurring at sites where the patient feels this is different from their previous experience, and potentially worse than the original condition. Risk factors listed include daily use of moderate to high potency products for at least a year in adults or two months in children, treatment of sensitive sites such as the face and genitals, onset within days to weeks after stopping, and patients with atopic dermatitis being at highest risk.

This item only makes sense if three parts travel together. The regulator described these reactions as very infrequent, attributed them to prolonged or inappropriate use, and in the same document told healthcare professionals to advise patients on the amount of product to be applied, because underuse can prolong treatment duration. Its other recommendations run the same way: prescribe the lowest potency needed, tell patients the recommended duration, consider reducing potency or application frequency for long-term users, and report reactions including those occurring after stopping. The regulator also required marketing authorization holders to add the risk and its features to product information and patient leaflets.

In Korea and Japan, topical steroid withdrawal tends to be treated either as an internet rumour or as absolute truth. What the UK material supplies is the coordinate between those two: a matter a regulator reviewed and had written into product information, and one the same regulator called very infrequent while noting that underuse is also a problem. This article does not decide whether topical corticosteroids are safe or dangerous. What each country's guidelines and regulators wrote down is where its job ends.

Who pays for moisturizer?

Table: where atopic dermatitis emollients sit in each country's reimbursement and prescribing system. The same first-line treatment falls into a different box depending on the country.

The cost-sharing cells for the United States and Japan were left empty because the sources were not obtained. Korea's moisturizer coverage status rests on a single municipal document and the national picture was not verified. Leaving the blanks blank is what keeps the rest of the table worth reading.

What can you change tomorrow?

Everything below is taken from national guidelines and public bodies. A guideline is a country-level recommendation rather than a prescription written for you, so the method and the amount that suit your own skin are settled with a clinician. That goes double for children, pregnancy and severe disease.

Apply immediately after washing. The European guideline puts soak and seal, applying emollient right after gently patting dry following a bath or shower, at strong recommendation with 100% consensus. Japan's guideline says to apply emollient promptly after bathing, and that one of the two daily applications is desirably straight afterwards.

Change formulation with the season. Hydrophilic formulations in summer, higher lipid content in winter, suggested by the European guideline. Of the guidelines examined here, it was the only one that raised seasonal formulation at all.

Widen the area you cover. Japan's guideline says application to the whole body including areas that look normal is desirable. UK guidance says emollients should be used on the whole body even when the eczema is clear. As a unit of amount, both the Korean and Japanese guidelines carry the fingertip unit: the length squeezed from a 5mm nozzle along an adult's terminal index finger phalanx, about 0.5g, covers roughly two adult palms, around 2% of body surface area.

Whether to use less soap or more depends on the site and the season. Japan's guideline treats soap and cleansers as a conditional recommendation. Minimize use and rinse thoroughly with water that is not too hot where dryness is severe or a product is strongly irritating; consider active cleanser use for oily skin, sebum-rich sites and sites with repeated infection. It states there is no evidence that bar soap or liquid cleanser is superior, and includes the split-limb trial in which four weeks of soap on one side and water only on the other produced no difference in eruption scores.

If ointment residue bothers you. Residue from petrolatum-based ointments can resist soap and cleanser, and Japan's guideline says applying something like olive oil to the bothersome areas can be considered.

Do not mix your own preparations. Combining two or more topical products yourself, a corticosteroid with an emollient for instance, should not be done casually, because drug stability and percutaneous absorption are expected to change.

Manage sweat instead of avoiding it. There is no evidence that instructing patients to avoid sweating improves symptoms, per Japan's guideline. The school-coordination form used there lists wiping down with a damp towel after sweating and showering if possible among its example accommodations.

Dust mite avoidance has a defined target group. Korea's guideline suggests avoidance only for patients who are sensitized and have a clear history of skin worsening linked to exposure. The strategies listed are indoor humidity control, washing bedding at 55 to 60C, HEPA filtration and reducing fabric furnishings. These are not recommended for primary prevention of atopic dermatitis.

If you want to start maintenance therapy, book the reviews at the same time. The European definition of proactive therapy includes a predefined appointment schedule, and Japan's guideline says it is desirable for it to be carried out by, or in coordination with, a physician well versed in assessing atopic skin signs. It was not designed as something you start and finish alone.

Check what you are actually entitled to. Korea has a special cost-sharing scheme attached to the severe atopic dermatitis code, and biologic reimbursement criteria defined partly by EASI score, and some municipalities support moisturizers from a separate budget, which makes the local public health centre's own notice the thing to check. In the UK, emollients are prescribable for active eczema, with the quantity and the supply for nurseries and schools written into guidance. The insurance structure in the United States is something this article was not able to confirm.

Is a bleach bath worth trying?

This is a good place to watch one therapy split four ways. The United States issued a conditional suggestion that patients with moderate to severe atopic dermatitis use dilute bleach baths in addition to topical therapy, rather than usual baths, and attached a practical supplement to it. The European guideline issued a weak recommendation limited to patients with a history of recurrent skin infections. Japan's guideline states that no domestic guidance exists and that development is awaited. Korea's main recommendation table has no entry. What split was not whether evidence exists but who the therapy is for.

The evidence does not point one way either. A 2017 systematic review and meta-analysis pooled five studies and concluded that bleach baths do reduce severity but do not appear more effective than water baths, with no significant difference observed between bleach and water baths at four weeks; of four studies making a direct comparison, two favoured bleach, one favoured water alone and one found no significant difference. A different meta-analysis in 2022, including unpublished data across ten trials and 307 participants, estimated the probability of a 50% improvement in severity at 32% with adjunctive dilute bleach baths against 22% for controls, at moderate certainty. Differences in adverse events were minimal and the mild cases were skin dryness and irritation, but changes in other patient-important outcomes, itch, patient-reported severity, sleep quality, quality of life and flare risk, were uncertain. The European guideline adds one more line: the Cochrane review it cites found no difference in overall improvement at one month, which it says corresponds to recent data showing no antimicrobial effect in vitro of diluted bleach baths. That the evidence behind a widely known therapy can split this far is the content of this section.

The two contraindications in the American practical supplement are the part to carry away: asthma that is not controlled, because inhalation risks provoking a flare, and contact dermatitis to bleach. The same document states that bleach baths are an addition to standard eczema skin care and do not replace it, says to avoid products with fragrance or additives and so-called splashless types, and to rinse with lukewarm water afterwards and continue usual skin care. Ventilate the bathroom well, since bleach odour and vapour can irritate the nose and lungs, and do not do this straight after cleaning the tub with an ammonia-based cleaner, because dangerous gases can form. Swallowing the bathwater can cause abdominal pain, nausea and vomiting, and depending on severity may need emergency care. Stop if eye, nose or throat irritation or an asthmatic reaction occurs, and consider stopping if there has been no response after four weeks. On pregnancy the document says it is generally considered safe but that no rigorous study has addressed the question directly. What the trials used was a final concentration of about 0.005% sodium hypochlorite in lukewarm water, ten minutes at a time, twice a week, over trial periods of 4 to 16 weeks.

This article does not print a mixing method. It is not a treatment order, the recommended population differs by country, and whether those two contraindications apply to you is not something an article can determine. If you are considering it, that judgement belongs with the clinician who treats you.

Before you spend money

Start with supplements, where the numbers in the Korean guideline's recommendation table are lower than most people would guess. Probiotics and prebiotics: recommendation strength C, evidence 2b, mean expert agreement score 6.68 with 52% of respondents agreeing. Vitamin D: C, 2b, mean 6.76 with 56%. Evening primrose oil: C, 2b, mean 7.52 with 80%. All three are graded as proposing limited use rather than recommending, and for two of them only about half the expert panel agreed.

Dietary restriction is a decision that comes after a diagnosis. A Cochrane review suggests removing egg from the diet can help control atopic dermatitis in patients sensitized to egg, but strict elimination diets are recommended only for allergies diagnosed by a specialist, and general avoidance of gluten, egg or milk is not recommended for patients not specifically diagnosed with that food allergy, according to the Korean guideline. Japan's guideline adds a breastfeeding case: where removing a suspected food from the mother's diet improved symptoms, keeping remission for one to two months with topical therapy and then resuming breastfeeding with the mother eating that food again often produces no worsening, so there are many cases in which long-term maternal elimination or stopping breastfeeding is unnecessary even where sensitization exists. UK guidance covers formula-fed infants under six months with moderate to severe atopic eczema, offering a 6 to 8 week trial of extensively hydrolysed protein or amino acid formula, referring to specialist dietetic advice if a cow's milk-free diet runs past eight weeks, and stating that unmodified alternative milk proteins and partially hydrolysed formulas should not be used.

The idea of preventing eczema by applying emollient from birth is widespread. The Korean guideline's answer is a hold. Emollients may be applied as a secondary or tertiary prevention strategy, but their role in primary prevention in infancy needs further confirmation, and the results of systematic reviews conflict, with some emphasizing possible benefit in high-risk infants and others reporting no significant effect.

Pets are an item where the evidence runs against the folk advice. Avoidance is recommended for patients with confirmed sensitization and allergy. But exposure during pregnancy or in infancy may lower the risk of developing atopic dermatitis. One birth cohort suggested pet ownership in infancy was inversely associated with atopic dermatitis risk at age five, and in a meta-analysis, children exposed to a dog or cat during pregnancy, infancy or childhood had a 25% lower risk. So avoiding pets solely to prevent atopic dermatitis is not recommended.

Several things have been assessed and found wanting. Silver-containing textiles have eight randomized trials behind them, too heterogeneous in design to pool, with no clear benefit reported. Alpine high-altitude climate therapy has 15 observational studies covering more than 40,000 people, and the European guideline still could not make a recommendation either way, because there are no controlled trials and therefore no reliable data on which element of the therapy produced the observed effects. Oral antibiotics in the absence of signs of infection have no reports of efficacy and are not recommended. Povidone-iodine solution lacks the evidence to be actively recommended and, Japan's guideline says, should not be used casually, given the possibility of worsening dermatitis through irritation of eroded surfaces, allergic contact dermatitis, anaphylaxis and effects on thyroid function. The American guideline issued conditional recommendations against topical antimicrobials and antibiotics, topical antiseptics and topical antihistamines. The European guideline recommended against acupuncture, phytotherapy, autologous serum injection and Chinese herbal medicine as standard therapy, each at 100% expert consensus; for herbal medicine, the cited Cochrane review could not conclude superiority over other control interventions because of methodological weaknesses and found no conclusive evidence that oral or topical herbal medicine reduces eczema severity in children or adults. That judgement is about a place in standard therapy, not an assessment of traditional medicine as a whole. On bacterial swab culture, the European guideline says it is usually not helpful, because it does not change the treatment approach unless the infection involves a resistant organism.

Why do countries treat steroids so differently?

The reason management differs by country is not that the evidence differs by country. The papers cited overlap heavily. What differs is who a therapy is for, who pays, and how afraid of corticosteroids people in that country are.

The third one has actually been measured. A multicentre study across 21 hospitals in 17 countries analysed 1,564 participants from 15 countries, with patients aged three months and older, or their parents or legal guardians, completing a validated translation of the TOPICOP questionnaire in each country's language. The global score was 44.7 plus or minus 20.5%, with subscores of 37.0 plus or minus 22.8% for knowledge and beliefs, 54.7 plus or minus 27.8% for fears, and 50.1 plus or minus 29.1% for behaviour. Fear runs ahead of knowledge. The study's conclusion reads: global scores and subscores differed between countries, although the subscores did not always vary in parallel, suggesting different levels of topical corticosteroid phobia and different drivers for each country. Which countries scored high or low is something this article could not verify and therefore does not say.

A 2025 study remeasured the same scale in Japan. It was funded by a pharmaceutical company, Otsuka Pharmaceutical, and three of its authors are employees of that company, which has to be stated alongside any citation of it. Combining a health insurance claims database with an online survey, it covered 1,507 adults with atopic dermatitis, 525 caregivers of children with it, 1,204 adults without it and 1,539 caregivers of children without it. Global scores were 42.5 plus or minus 18.9 for adults with atopic dermatitis and 41.7 plus or minus 18.6 for caregivers of affected children, against 41.8 plus or minus 19.6 for adults without it and 41.3 plus or minus 18.9 for caregivers of unaffected children. As in the international study, the fears domain drew the highest agreement of the three. The values sat close to the 40.3 to 41 range found in earlier Japanese surveys from 2014 to 2016, meaning the number barely moved even after the treatment landscape changed substantially.

The figure that stays with you from that study is not a proportion but a comparison. People without atopic dermatitis scored almost the same as patients. If that holds, this fear is less a product of living with the disease than something the wider society shares, and patient education alone would not be enough of an answer.

Which brings the article to its point. Three countries met the same problem with three different instruments. The Korean society put a structured patient education programme at recommendation strength A and named steroid phobia as a barrier to adherence. The Japanese society kept a section on inpatient treatment and listed corticosteroid avoidance among the reasons patients end up needing it. The UK regulator reviewed withdrawal reactions, had them written into product information, and in the same document noted that underuse prolongs treatment. The European guideline suggested that therapeutic patient education programmes with proven efficacy be widely implemented, citing a meta-analysis of seven randomized trials in 1,853 children evaluating parental education, where the standardized mean difference in severity score was -8.22; no significant between-group difference was found in quality of life, and the guideline notes that programme formats vary widely with cultural background and health system and that the optimal mode of delivery has not been settled. In Germany, an adult programme was tested in a multicentre randomized trial: 315 adults with moderate to severe disease split between an intervention group and a waiting-list group, with the intervention receiving a 12-hour education manual agreed by multidisciplinary teams across several centres, and showing significant improvement over the waiting list at one year in itch coping, quality of life and severity.

The European guideline also contains a sentence that states this article's premise for it. Among the costs patients and carers face in managing atopic eczema, it lists purchasing treatments when these are not reimbursed, giving emollients in some countries as the example, and then says national healthcare provisions and insurance regulations vary widely country by country and for individuals, leading to significant health inequalities which must be addressed urgently. Which country is right is not something this article settles. That the same fear has produced three institutional answers, education, admission and regulation, is what the sources support.

When should you see a specialist?

What follows comes from UK national guidance, the Japanese society guideline and the European guideline. This article does not diagnose. Do not use the patterns below to decide for yourself whether something is infection or a flare; use them to decide when to be seen.

Same-day care. Rapidly worsening painful eczema, clustered blisters resembling cold sores, punched-out erosions, possibly with fever and lethargy: UK guidance recommends immediate same-day referral for specialist dermatological advice if eczema herpeticum is suspected. Where the skin around the eyes is involved, referral for same-day ophthalmological and dermatological advice alongside systemic antiviral treatment (aciclovir) is recommended. Japan's guideline describes the same condition as arising from primary infection or reactivation of herpes simplex virus, appearing unlike ordinary herpes simplex as numerous small blisters and pustules over eczematous lesions centred on the face and neck, accompanied by fever and lymph node swelling, sometimes with secondary bacterial infection, and in some cases difficult to distinguish from pyoderma.

Signs suggesting bacterial infection. Weeping, pustules, crusts, treatment failure, rapidly worsening disease, fever and malaise are the signs UK guidance lists. The caveat the European guideline attaches has to be read with them. Most patients with atopic eczema colonized by Staphylococcus aureus show no overt signs of infection such as weeping, honey-coloured crusts or pustules, and the signs of skin inflammation during a flare can overlap with the signs of skin infection, making infection itself tricky to diagnose. If experts find that distinction hard, this list is not a self-assessment tool. It is a tool for deciding when to book.

Suspected cellulitis. Where a sharply demarcated area of redness and swelling develops with local heat and pain, on the lower leg for example, Japan's guideline says systemic antibacterial treatment and rest are needed.

Referral within two weeks. Where the atopic eczema is severe and has not responded to optimum topical therapy after one week, or where treatment of bacterially infected atopic eczema has failed. Non-urgent referral criteria cover a diagnosis that is or has become uncertain, eczema not controlled satisfactorily by management, facial eczema, difficulty applying treatments, suspected contact allergic dermatitis, and significant psychosocial impact.

Eyes can need checking even without symptoms. Ocular complications of atopic dermatitis include blepharitis, keratoconjunctivitis, keratoconus, cataract, glaucoma, retinal detachment and bacterial or viral infection, and they arise more readily in patients with severe or refractory facial eruptions. Japan's guideline states that patients with atopic dermatitis sometimes have ocular complications without any ophthalmic complaint, and that these can progress to irreversible visual impairment, so dermatologists should stay conscious of them and arrange ophthalmological examination to preserve visual function. Controlling eruptions around the eyes adequately is described as important for prevention.

If the pattern looks like withdrawal, do not decide alone. Within days to weeks of stopping a topical corticosteroid, skin changes can appear in which burning rather than itch is the main symptom, redness is confluent rather than patchy, the area extends beyond the site first treated, and it feels different from anything previously experienced. It can be worse than the original condition. The UK regulator's document does not leave that judgement to the patient; it has clinicians adjust potency or application frequency. One conclusion survives: instead of stopping on your own or pushing on regardless, describe this pattern to a clinician.

This list is not exhaustive. The items above are extracts from national guidelines, and any other symptom that is severe or concerning is worth discussing with a clinician.

Frequently asked questions

Frequently asked

Does sweating make eczema worse?

Japan's dermatology guideline addresses this directly and says there is no evidence that instructing patients to avoid sweating improved symptoms, so such instruction is unnecessary. What it emphasizes instead is guidance on dealing with sweat afterwards, and it goes further: in cases where sweating is reduced, becoming able to sweat again can be one of the goals treatment aims for. The school-coordination form used in Japan lists wiping down with a damp towel after sweating, and showering where possible, among its example accommodations.

Does bathing every day make it worse?

Not according to the meta-analysis cited in Japan's guideline, which found no association between daily showering or bathing and worsening severity, and no statistically significant difference in effectiveness between seven or more times a week and fewer. Showering itself carries a recommendation there, at grade 1 and evidence level B, supported partly by three Japanese trials of tap-water showers taken at school. Water temperature is where the guidelines differ: Japan's says 38 to 40C and that 42C or above cannot be recommended, while Korea's says 27 to 30C for 5 to 10 minutes. This article cannot say which is right, because the Korean guideline moved the basis for its figure to supplementary material that was not obtained, and in the European guideline the same 27 to 30C appears as the temperature for a rapid rinse.

Should I try a bleach bath?

That depends on where you are and who you are, and it is a decision for your clinician. The four guidelines place this therapy differently: a conditional suggestion for moderate to severe disease with a practical supplement in the United States, a weak recommendation limited to patients with recurrent skin infections in Europe, an explicit statement that no domestic guidance exists in Japan, and no entry in Korea's main recommendation table. The two meta-analyses reached different conclusions, and the European guideline notes recent data showing no antimicrobial effect in vitro. Two contraindications are in the American practical supplement: asthma that is not controlled, and contact dermatitis to bleach. This article does not print concentrations to mix or a method to follow.

Do probiotics or vitamin D help?

The Korean guideline's recommendation table grades probiotics and prebiotics at strength C with evidence 2b, mean expert agreement 6.68 and 52% of the panel agreeing, and vitamin D at C, 2b, mean 6.76 and 56%. Evening primrose oil is C, 2b, mean 7.52 and 80%. All three are framed as proposing limited use rather than as recommendations, which is a more precise answer than most product pages will give you.

Is using a topical steroid twice a week for months safe?

This article does not adjudicate that, and the honest answer is a set of quotations. Japan's guideline reports no significant difference in adverse events versus vehicle over observation periods of up to 20 weeks for corticosteroids and up to one year for tacrolimus, and states plainly that no examination has been carried out beyond those periods and careful observation is necessary. The European definition of the therapy includes a predefined schedule of clinical examinations, and Japan's guideline wants it run by or with a physician experienced in assessing atopic skin. The UK regulator described withdrawal reactions as very infrequent, tied them to prolonged or inappropriate use, and in the same document told clinicians to advise patients how much to apply, because underuse can prolong treatment. All of which points at the same practical answer: this is a plan to make with a clinician, with review dates in it.